Years Isolated from Italian Students Aged 14 to 22 Neisseria meningitidis Carrier Strains Molecular and Serological Diversity of
暂无分享,去创建一个
Isabella | Donatella | F. Ansaldi | A. Orsi | M. Pizza | M. Giuliani | B. Brunelli | R. Gasparini | D. Amicizia | Icardi | P. Canepa | M. Moschioni | G. C. Angelis | E. Rizzitelli | Sara Comandi | G. Boccadifuoco | Panatto | Simmini | Ștefania | Giancarlo | Stefania
[1] M. Snape,et al. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? , 2013, Expert review of vaccines.
[2] C. Donati,et al. Conservation of Meningococcal Antigens in the Genus Neisseria , 2013, mBio.
[3] R. Rappuoli,et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. , 2013, The Lancet. Infectious diseases.
[4] L. Rubin,et al. Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale , 2013, MMWR. Morbidity and mortality weekly report.
[5] John L. Perez,et al. Potential impact of the bivalent rLP2086 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease , 2012, Human vaccines & immunotherapeutics.
[6] R. Rappuoli,et al. Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines , 2012, Clinical and Vaccine Immunology.
[7] R. Gasparini,et al. Neisseria meningitidis, pathogenetic mechanisms to overcome the human immune defences. , 2012, Journal of preventive medicine and hygiene.
[8] L. Harrison,et al. The changing and dynamic epidemiology of meningococcal disease. , 2012, Vaccine.
[9] P. Dull,et al. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease. , 2012, Vaccine.
[10] S. Meri,et al. Capsule null locus meningococci: typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine. , 2012, Vaccine.
[11] C. Hogea,et al. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region , 2011, Expert review of anti-infective therapy.
[12] L. Harrison,et al. Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates. , 2011, Vaccine.
[13] D. Toneatto,et al. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans , 2011, Human vaccines.
[14] J. Findlow,et al. Molecular Targets in Meningococci: Efficient Routine Characterization and Optimal Outbreak Investigation in Conjunction with Routine Surveillance of the Meningococcal Group B Vaccine Candidate, fHBP , 2010, Clinical and Vaccine Immunology.
[15] C. Napoli,et al. Young-adult carriers of Neisseria meningitidis in Puglia (Italy): Will the pattern of circulating meningococci change following the introduction of meningococcal serogroup C conjugate vaccines? , 2010, Human vaccines.
[16] M. May,et al. Meningococcal carriage by age: a systematic review and meta-analysis. , 2010, The Lancet. Infectious diseases.
[17] M. Pizza,et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine , 2010, Clinical and Vaccine Immunology.
[18] R. Rappuoli,et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans , 2010, Proceedings of the National Academy of Sciences.
[19] M. Virji,et al. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease , 2010, Clinical science.
[20] P. Mastrantonio,et al. Neisseria meningitidis Serogroup X Sequence Type 2888, Italy , 2010, Emerging infectious diseases.
[21] M. Pizza,et al. Characterization of fHbp, nhba (gna2132), nadA, porA, Sequence Type (ST), and Genomic Presence of IS1301 in Group B Meningococcal ST269 Clonal Complex Isolates from England and Wales , 2009, Journal of Clinical Microbiology.
[22] M. Maiden,et al. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs , 2009, Expert review of vaccines.
[23] Lee H Harrison,et al. Global epidemiology of meningococcal disease. , 2009, Vaccine.
[24] P. Manfredi,et al. On the relationship between meningococcal transmission dynamics and disease: remarks on humoral immunity. , 2009, Vaccine.
[25] R. Rappuoli,et al. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. , 2009, Vaccine.
[26] R. Rappuoli,et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. , 2009, Vaccine.
[27] R. Reintjes,et al. Longitudinal study of meningococcal carrier rates in teenagers. , 2008, International journal of hygiene and environmental health.
[28] D. Crook,et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. , 2008, The Journal of infectious diseases.
[29] S. Chanteau,et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] K. Jolley,et al. A surveillance network for meningococcal disease in Europe. , 2007, FEMS microbiology reviews.
[31] D. Caugant,et al. Lessons from meningococcal carriage studies. , 2007, FEMS microbiology reviews.
[32] D. Caugant,et al. Pharyngeal carriage of Neisseria meningitidis in 2-19-year-old individuals in Uganda. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[33] N. Andrews,et al. Social Behavior and Meningococcal Carriage in British Teenagers , 2006, Emerging infectious diseases.
[34] L. McCallum,et al. The VR2 Epitope on the PorA P1.7-2,4 Protein Is the Major Target for the Immune Response Elicited by the Strain-Specific Group B Meningococcal Vaccine MeNZB , 2006, Clinical and Vaccine Immunology.
[35] Daniel J. Wilson,et al. Distribution of Serogroups and Genotypes among Disease-Associated and Carried Isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway , 2004, Journal of Clinical Microbiology.
[36] Edward C. Holmes,et al. Distribution of Surface Protein Variants among Hyperinvasive Meningococci: Implications for Vaccine Design , 2004, Infection and Immunity.
[37] D. Caugant,et al. Neisseria meningitidis: an overview of the carriage state. , 2004, Journal of medical microbiology.
[38] R. Rappuoli,et al. NadA Diversity and Carriage in Neisseria meningitidis , 2004, Infection and Immunity.
[39] M. Cafferkey,et al. PCR-Based Assay for Detection of Neisseria meningitidis Capsular Serogroups 29E, X, and Z , 2004, Journal of Clinical Microbiology.
[40] M. Unemo,et al. Analysis of PorA variable region 3 in meningococci: implications for vaccine policy? , 2003, Vaccine.
[41] S. Clarke,et al. Identification of Neisseria meningitidis Serogroups Y and W135 by siaD Nucleotide Sequence Analysis , 2003, Journal of Clinical Microbiology.
[42] D. Stephens,et al. Genetic basis for nongroupable Neisseria meningitidis. , 2003, The Journal of infectious diseases.
[43] Jeannette Adu-Bobie,et al. Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870 , 2003, The Journal of experimental medicine.
[44] T. Popović,et al. Sequence Diversity of Neisseria meningitidis 16S rRNA Genes and Use of 16S rRNA Gene Sequencing as a Molecular Subtyping Tool , 2002, Journal of Clinical Microbiology.
[45] Anne Perrocheau,et al. Outbreak of Serogroup W135 Meningococcal Disease after the Hajj Pilgrimage, Europe, 2000 , 2002, Emerging infectious diseases.
[46] R. Rappuoli,et al. NadA, a Novel Vaccine Candidate of Neisseria meningitidis , 2002, The Journal of experimental medicine.
[47] M. Maiden,et al. Many carried meningococci lack the genes required for capsule synthesis and transport. , 2002, Microbiology.
[48] M. Unemo,et al. Genosubtyping by sequencing group A, B and C meningococci; a tool for epidemiological studies of epidemics, clusters and sporadic cases , 2000, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[49] M. Taha,et al. Simultaneous Approach for Nonculture PCR-Based Identification and Serogroup Prediction of Neisseria meningitidis , 2000, Journal of Clinical Microbiology.
[50] M. Achtman,et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[51] S. Hammerschmidt,et al. Capsule phase variation in Neisseria meningitidis serogroup B by slipped‐strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease , 1996, Molecular microbiology.
[52] T. Rønne,et al. Comparative studies on pharyngeal carriage of Neisseria meningitidis during a localized outbreak of serogroup C meningococcal disease. , 1993, Scandinavian journal of infectious diseases.
[53] M. Leinonen,et al. ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS Implications for Vaccine Development and Pathogenesis , 1983, The Lancet.
[54] J. D. Abbott,et al. The meningococcal carrier-rate. , 1973, Lancet.
[55] M. Artenstein,et al. Human immunity to the meningococcus. II. Development of natural immunity. , 1969 .
[56] M. Artenstein,et al. HUMAN IMMUNITY TO THE MENINGOCOCCUS I. THE ROLE OF HUMORAL ANTIBODIES , 1969 .